Development of the Cotton Rat Model of Rhinovirus Infection and Disease

棉鼠鼻病毒感染和疾病模型的建立

基本信息

  • 批准号:
    8360839
  • 负责人:
  • 金额:
    $ 27.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-06-11 至 2014-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Human rhinoviruses (HRVs) are the most common cause of colds and flu-like illnesses. In addition, HRV infections are associated with disease of considerable severity, such as exacerbation of asthma, wheezing illness in children, and chronic obstructive pulmonary disease (COPD). The morbidity and mortality attributable to rhinovirus infection is considerable and results in billions of dollars of health care cost every year. Despit the significance of the problem, no effective prevention of HRV infection or treatment of HRV-associated disease is currently available. Attempts to develop a small animal model of HRV infection in many species, from mice to monkeys, have failed, thus severely hampering mechanistic studies and the development of vaccines and therapeutics against HRV infection. Unlike the laboratory mouse and rat, the cotton rat (Sigmodon hispidus) exhibits a unique susceptibility to infection by human viruses and has become a preferred model for a number of human respiratory pathogens including respiratory syncytial virus (RSV), influenza (A and B), adenoviruses (several serotypes), parainfluenza virus (type 3), and measles. The long term goal of this project is to use the cotton rat to establish a reliable model of HRV infection. Based on the well-documented susceptibility of the cotton rat to a diversity of human viruses and our own preliminary studies indicating that intranasal infection with HRV16 results in respiratory tract pathology in the cotton rat we proposed to First, Delineate the characteristics of acute HRV16 infection in cotton rats by (a) defining the kinetics of HRV16 infection; (b) selecting clinical parameters that can be use to follow acute disease; (c) describing the HRV16-induced pathology of the upper and lower respiratory tract; and (d) defining the expression of cytokines and chemokines resulting from HRV-16 infection. Secondly, we will focus in the characterization of the protective immunological response generated by HRV16 infection in the cotton rats. A strong team of investigators has been assembled combining extensive expertise in the use of cotton rats and strong virology capabilities. If successful, the proposed research will result in a valuable experimental resource to test vaccines and therapeutics against the "common cold". PUBLIC HEALTH RELEVANCE: Human rhinoviruses are the cause of most common colds and flu-like illnesses. In addition rhinovirus infections are associated with disease of considerable severity, such as exacerbation of asthma, wheezing illness in children, and chronic obstructive pulmonary disease. Attempts to develop a small animal model of rhinovirus infection in many animal species have failed, thus severely hampering mechanistic studies and the development of vaccines and therapeutics against HRV infection. The purpose of this project is to generate for the first time a model of rhinovirus infection using the cotton rat
描述(由申请人提供):人类鼻病毒(HRV)是感冒和流感样疾病的最常见原因。此外,HRV感染与严重程度相当严重的疾病有关,例如哮喘的加剧,儿童喘息疾病和慢性阻塞性肺部疾病(COPD)。可归因于鼻病毒感染的发病率和死亡率相当大,每年导致数十亿美元的医疗保健费用。鄙视问题的重要性,目前没有有效预防HRV感染或HRV相关疾病的治疗。从小鼠到猴子的许多物种中开发小型HRV感染的小动物模型的尝试已经失败,因此严重阻碍了机理研究以及疫苗和治疗剂的开发,以防止HRV感染。与实验室小鼠和大鼠不同,棉花大鼠(Sigmodon hispidus)表现出对人类病毒感染的独特敏感性,并已成为许多人类呼吸道病原体(包括呼吸综合病毒(RSV),流感(a和b))的首选模型。 ,腺病毒(几种血清型),Parainfluenza病毒(3型)和麻疹。该项目的长期目标是使用棉花大鼠建立可靠的HRV感染模型。基于棉花大鼠对多样化的人类病毒多样性的易感性和我们自己的初步研究表明,HRV16的鼻内感染会导致棉花大鼠的呼吸道病理学,我们首先提出,我们提出的是急性HRV16感染的特征(a)定义HRV16感染的动力学; (b)选择可用于急性疾病的临床参数; (c)描述上和下呼吸道的HRV16诱导的病理; (d)定义由HRV-16感染引起的细胞因子和趋化因子的表达。其次,我们将集中于棉花大鼠HRV16感染产生的保护性免疫反应的表征。一支强大的调查人员团队已经组合了在使用棉花大鼠和强大的病毒学能力方面的广泛专业知识。如果成功,拟议的研究将导致 有价值的实验资源,用于测试“普通感冒”的疫苗和治疗剂。 公共卫生相关性:人类鼻病毒是最常见的感冒和类似流感疾病的原因。另外,鼻病毒感染与严重程度相当严重的疾病有关,例如哮喘的加剧,儿童喘息疾病和慢性阻塞性肺部疾病。在许多动物物种中开发鼻病毒感染的小动物模型的尝试失败了,因此严重阻碍了机械性研究以及疫苗和治疗剂的开发,以防止HRV感染。该项目的目的是首次使用棉大鼠产生鼻病毒感染的模型

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JORGE C BLANCO其他文献

JORGE C BLANCO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JORGE C BLANCO', 18)}}的其他基金

Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)
RSV 诱导的 M2 巨噬细胞分化:TLR4/PPARg/RXR 信号轴的作用 (80)
  • 批准号:
    10418803
  • 财政年份:
    2021
  • 资助金额:
    $ 27.48万
  • 项目类别:
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)
RSV 诱导的 M2 巨噬细胞分化:TLR4/PPARg/RXR 信号轴的作用 (80)
  • 批准号:
    10287155
  • 财政年份:
    2021
  • 资助金额:
    $ 27.48万
  • 项目类别:
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury
靶向 TLR 信号通路以减弱病原体介导的急性肺损伤
  • 批准号:
    9306674
  • 财政年份:
    2017
  • 资助金额:
    $ 27.48万
  • 项目类别:
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury
靶向 TLR 信号通路以减弱病原体介导的急性肺损伤
  • 批准号:
    10098763
  • 财政年份:
    2017
  • 资助金额:
    $ 27.48万
  • 项目类别:
Development of VLP vaccine for RSV
RSV VLP 疫苗的开发
  • 批准号:
    9897525
  • 财政年份:
    2014
  • 资助金额:
    $ 27.48万
  • 项目类别:
Development of VLP vaccine for RSV
RSV VLP 疫苗的开发
  • 批准号:
    9137089
  • 财政年份:
    2014
  • 资助金额:
    $ 27.48万
  • 项目类别:
Development of VPL Vaccine for RSV
RSV VPL 疫苗的开发
  • 批准号:
    8645890
  • 财政年份:
    2014
  • 资助金额:
    $ 27.48万
  • 项目类别:
Development of VLP vaccine for RSV
RSV VLP 疫苗的开发
  • 批准号:
    9334692
  • 财政年份:
    2014
  • 资助金额:
    $ 27.48万
  • 项目类别:
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
Eritoran (E5564),一种 TLR4 拮抗剂,作为流感的新型治疗剂
  • 批准号:
    8884533
  • 财政年份:
    2013
  • 资助金额:
    $ 27.48万
  • 项目类别:

相似国自然基金

影像组学用于急性病毒性肺炎鉴别诊断的生物学机制探究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
胆碱能抗炎通路调节巨噬细胞M1/M2极化在CVB3诱导的急性病毒性心肌炎中的作用及机制研究
  • 批准号:
    81870281
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
急性病毒感染中转录因子Tbet对TFH应答的调控及机制研究
  • 批准号:
    31700774
  • 批准年份:
    2017
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
调控巨噬细胞极化的microRNA分子鉴定及其在CVB3诱导的急性病毒性心肌炎中的作用
  • 批准号:
    81472017
  • 批准年份:
    2014
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目
新发急性病毒性传染病免疫预防的实验研究
  • 批准号:
    30471544
  • 批准年份:
    2004
  • 资助金额:
    22.0 万元
  • 项目类别:
    面上项目

相似海外基金

Development of Patient-Tailored Adaptive Treatment Strategies for Acute Severe Ulcerative Colitis
制定针对急性重症溃疡性结肠炎的患者定制适应性治疗策略
  • 批准号:
    10569397
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Optimizing Use of Advanced Diabetes Technology for Self-Management in Adolescents with Type 1 Diabetes: Integration of Real-Time Glucose and Narrative Data
优化使用先进糖尿病技术对 1 型糖尿病青少年进行自我管理:实时血糖和叙述数据的集成
  • 批准号:
    10569293
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Effect of Medicaid Accountable Care Organizations on Behavioral Health Care Quality and Outcomes for Children
医疗补助责任护理组织对儿童行为保健质量和结果的影响
  • 批准号:
    10729117
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
The National Couples Health and Time Use Stress Biology Study (NCHAT-BIO): Biobehavioral Pathways to Population Health Disparities in Sexual Minorities
全国夫妻健康和时间使用压力生物学研究 (NCHAT-BIO):性别少数人口健康差异的生物行为途径
  • 批准号:
    10742339
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Mindfulness-Based Stress Reduction in Adolescents with Type 1 Diabetes
基于正念的 1 型糖尿病青少年减压
  • 批准号:
    10552006
  • 财政年份:
    2022
  • 资助金额:
    $ 27.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了